Dividend Distribution - The company plans to distribute a cash dividend of 0.1 yuan per 10 shares and a capital reserve increase of 3 shares per 10 shares based on a base of 173,342,000 shares[6]. - A cash dividend of RMB 0.1 per share (totaling RMB 1,733,420) will be distributed, with a capital reserve conversion of 3 shares for every 10 shares held[113]. - The cash dividend payout ratio for 2019 was 26.29% of the net profit attributable to shareholders[120]. - The cash dividend payout ratio for 2018 was 27.15% of the net profit attributable to shareholders[120]. - The total cash dividends distributed in 2019 amounted to RMB 1,733,420.00, while the total for 2018 was RMB 2,008,762.50[120]. - In 2015, the company distributed a cash dividend of RMB 0.50 per 10 shares, totaling RMB 6,667,000.00[116]. - No cash dividends were distributed for the years 2016 and 2017, nor were there any stock bonuses or capital reserve transfers[116][117]. - In 2018, the company distributed a cash dividend of RMB 0.15 per 10 shares, totaling RMB 2,008,762.50, and issued 40,175,250 bonus shares[118]. - For 2019, the proposed cash dividend was RMB 0.10 per 10 shares, totaling RMB 1,733,420.00, along with a transfer of 52,002,600 bonus shares[118]. Financial Performance - The company's operating revenue for 2019 was RMB 224,064,704.39, representing a 30.24% increase compared to RMB 172,042,840.49 in 2018[19]. - The net profit attributable to shareholders for 2019 was RMB 6,592,620.34, a decrease of 10.91% from RMB 7,399,910.67 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was RMB 1,837,396.93, down 52.94% from RMB 3,904,677.45 in 2018[19]. - The net cash flow from operating activities was RMB 85,874.81, a significant decline of 99.68% compared to RMB 27,059,863.81 in the previous year[19]. - The total assets at the end of 2019 were RMB 633,081,946.60, an increase of 4.47% from RMB 606,022,667.36 at the end of 2018[19]. - The net assets attributable to shareholders at the end of 2019 were RMB 422,651,741.36, up 2.45% from RMB 412,547,766.99 in 2018[19]. - The company reported a basic earnings per share of RMB 0.0380, down 11.01% from RMB 0.0427 in 2018[19]. - The company achieved total revenue of ¥224,064,704.39 in 2019, representing a year-on-year growth of 30.24%[54]. - The net profit attributable to the parent company was ¥6,592,620.34, a decrease of 10.91% compared to the previous year[54]. Business Strategy and Development - The company aims to enhance its risk resistance by developing innovative drug clinical services and preclinical services, leveraging its industry experience and talent advantages[4]. - The company is focusing on developing new business areas such as preclinical research services and CDMO services, facing potential challenges due to existing competitive players in the market[6]. - The company is committed to adjusting its business structure and development direction in response to changes in drug approval policies by NMPA[4]. - The company aims to meet customer needs and accelerate drug development processes to benefit patient health[28]. - The company is focusing on establishing partnerships with multinational pharmaceutical companies for international multi-center clinical research services[102]. - The company plans to invest in healthcare product R&D and pursue mergers and acquisitions to enhance its industry layout and core competitiveness[104]. - The company will continue to develop its CDMO services and expand its business chain in the R&D and production service areas[104]. - The company aims to integrate its services from drug research to production, establishing a one-stop CRO service model[101]. - The company plans to focus on the CRO industry, aiming to develop a comprehensive new drug research platform over the next three to five years[101]. Risk Management - The company acknowledges the risk of contract execution delays due to the complexity of new drug development, which may lead to budget management challenges and potential cost overruns[5]. - The company has established a risk-sharing mechanism in contracts to address potential losses due to unforeseen circumstances during the execution of long-term projects[5]. - The company recognizes the need for careful project evaluation and strict process management to minimize project delays and associated penalties[5]. - The company anticipates potential risks from policy changes affecting new drug approvals and will adjust its business structure accordingly[105]. - The company is enhancing its management capabilities to mitigate risks associated with expanding its operational scale and business scope[108]. Market Trends and Competition - The rapid growth of domestic CRO companies has intensified competition in the pharmaceutical R&D outsourcing industry, necessitating improved marketing and service levels[5]. - The global CRO industry market size reached $57.8 billion in 2018, with a projected growth to $95.1 billion by 2023, reflecting a CAGR of 10.47% from 2018 to 2023[32]. - The domestic CRO market size was approximately $5.8 billion in 2018, with expectations to grow to $21.4 billion by 2023, indicating a CAGR of 29.6% during the same period[33]. - The CRO industry in China is entering a golden era, driven by the shift of global pharmaceutical outsourcing orders to the Asia-Pacific region and the cost advantages from local engineering talent[33]. Operational Efficiency - The company emphasizes the importance of internal management and integration to improve operational efficiency as it scales its business[6]. - The company has developed a nationwide service network, facilitating high-frequency monitoring of clinical research processes[45]. - The company has implemented a standardized quality control system, improving the reliability and efficiency of clinical research services[42]. - The company aims to expand its clinical research service network and enhance quality control to solidify its competitive edge in the clinical research sector[102]. Research and Development - The company has engaged in some preclinical independent research and technology transformation services based on market trends and technical expertise[28]. - The company has developed multiple new drug and generic drug projects through independent research, leveraging its technical expertise and market trends[30]. - The company is conducting IND research for the targeted therapy drug RUNNOR9591 for drug-resistant lung cancer, which has received clinical research permission[78]. - The company has made significant advancements in inhalation formulations, completing efficacy studies for asthma treatment nebulizers[79]. - Research and development expenses increased by 35.56% to CNY 18,279,480.95, reflecting the company's increased investment in R&D[76]. - The company invested approximately ¥18.28 million in R&D in 2019, representing 8.16% of its operating revenue, an increase from 7.84% in 2018[81]. Subsidiaries and Investments - The company established a new wholly-owned subsidiary, Guangdong Guangji Investment Co., Ltd., during the reporting period[71]. - The company established a joint venture, Shenzhen Chenji Pharmaceutical Technology Co., Ltd., with a registered capital of RMB 30 million, in which the company holds a 10% stake[168]. - The company completed a capital increase for its subsidiary, Guangzhou Boji Biomedical Technology Park Co., Ltd., with the registered capital increasing from 112 million RMB to 121.57 million RMB, reducing the company's ownership from 100% to 94.59%[166]. - The company invested in establishing a new subsidiary, Xinxiang Boji Pharmaceutical Technology Co., Ltd., with a registered capital of 10 million RMB, of which the company contributed 8 million RMB (80%)[166]. Management and Governance - The company has maintained a stable management structure with no significant turnover in key positions over the past year[200]. - The management team includes 10 members, with a mix of roles including independent directors and supervisors[198]. - The average age of the senior management team is approximately 47 years, indicating a relatively experienced leadership[198]. - Wang Tingchun serves as both the chairman and general manager of the company[190]. - The company appointed Wei Fangqun as the new Secretary of the Board on October 28, 2019, following the resignation of Han Yuping[200].

Financial Performance - Operating revenue for the reporting period was CNY 48,786,229.04, representing a year-on-year increase of 33.98%[7] - Net profit attributable to shareholders was CNY 2,658,217.91, a significant increase of 588.26% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,290,363.54, up 290.47% year-on-year[7] - Basic earnings per share for the reporting period were CNY 0.0153, an increase of 595.45% compared to the same period last year[7] - Total operating revenue for Q3 2019 was CNY 48,786,229.04, an increase of 34% compared to CNY 36,413,303.19 in the same period last year[39] - Net profit for Q3 2019 reached CNY 3,600,393.69, a significant increase from CNY 1,796,981.31 in Q3 2018, representing a growth of 100%[40] - Earnings per share for Q3 2019 were CNY 0.0153, compared to CNY 0.0022 in the same quarter last year, reflecting a substantial increase[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 605,047,812.12, a decrease of 0.16% compared to the end of the previous year[7] - The company's current assets totaled CNY 267,740,071.04, down from CNY 281,618,574.83 at the end of 2018, representing a decrease of approximately 4.5%[29] - The company's total liabilities decreased to CNY 173,723,425.33 from CNY 182,309,914.41, a reduction of about 4.8%[31] - Short-term borrowings increased significantly to CNY 15,000,000.00 from CNY 7,665,419.80, representing an increase of about 96.2%[31] - The total liabilities decreased to CNY 131,203,766.59 from CNY 140,277,714.82 year-over-year, indicating a reduction of approximately 6%[37] - Total equity increased to CNY 427,896,746.19 from CNY 422,842,742.28, showing a slight growth of about 1%[37] Cash Flow - The company reported a net cash flow from operating activities of -CNY 820,449.64, a decrease of 124.48% compared to the same period last year[7] - The net cash flow from operating activities decreased by 124.48% to -¥820,449.64 from ¥3,351,380.44, mainly due to increased cost expenses[17] - The net cash flow from investment activities improved by 114.48% to ¥11,387,224.40 from -¥78,651,665.42, mainly due to the expiration of financial products[17] - Cash inflow from operating activities amounted to CNY 153,662,527.64, an increase from CNY 132,398,839.14 in the previous period[54] - The net cash flow from operating activities was negative at CNY -820,449.64, down from CNY 3,351,380.44 in the previous period[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,072[10] - The largest shareholder, Wang Tingchun, held 35.78% of the shares, amounting to 62,014,340 shares[10] - The company reported no overdue commitments from controlling shareholders or related parties during the reporting period[25] - There were no violations regarding external guarantees during the reporting period[25] - The company did not execute any cash dividend policy during the reporting period[25] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 2,785,066.76 during the reporting period[8] - The company reported a 90.51% increase in other income to ¥2,778,174.10 from ¥1,458,288.39, attributed to government subsidies related to daily operations[16] - The company reported a significant increase in other income, which rose to CNY 1,421,427.75 from CNY 971,189.71 in the previous year, marking a growth of 46%[39] Research and Development - Research and development expenses for Q3 2019 amounted to CNY 4,371,600.50, which is a 17% increase from CNY 3,728,231.70 in Q3 2018[39] - Research and development expenses increased to ¥11,707,456.13, up 26.0% from ¥9,299,376.64 year-on-year[45] Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to drive future growth[40] - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to enhance its competitive position in the biotechnology sector[63] - New product development initiatives are underway, aimed at leveraging technological advancements to improve product offerings and market reach[63] - The management emphasized the importance of maintaining financial stability while exploring innovative strategies for growth and market penetration[63]

Financial Performance - Total operating revenue for the first half of 2019 was ¥93,316,182.27, representing a 22.11% increase compared to ¥76,416,941.23 in the same period last year[17]. - Net profit attributable to shareholders decreased by 48.69% to ¥2,944,975.71 from ¥5,739,929.49 in the previous year[17]. - Net profit after deducting non-recurring gains and losses fell by 72.56% to ¥1,320,038.74 from ¥4,810,558.31 year-on-year[17]. - Basic earnings per share decreased by 48.64% to ¥0.0170 from ¥0.0331 in the previous year[17]. - Operating profit decreased to ¥3,356,946.80, down 39.91% year-on-year, while net profit attributable to shareholders fell by 48.69% to ¥2,944,975.71[44]. - The company reported a total comprehensive income for the first half of 2019 of CNY 3,299,938.46, down from CNY 6,345,665.18 in the first half of 2018[148]. - The company's total revenue for the first half of 2019 reached ¥93,316,182.27, representing a year-on-year growth of 22.11%[44]. Cash Flow and Assets - Net cash flow from operating activities increased significantly by 177.76% to ¥7,061,413.83 compared to ¥2,542,276.04 in the same period last year[17]. - The company’s cash and cash equivalents increased by 124.66% to ¥14,603,171.37, due to improved project repayments[51]. - The company’s cash and cash equivalents decreased to CNY 2,942,045.72 in the first half of 2019 from CNY 7,665,419.80 in the same period of 2018[143]. - The total cash inflow from investment activities in the first half of 2019 was ¥138,513,180.65, a substantial rise from ¥11,522,538.37 in the previous year[156]. - The total amount of entrusted financial management during the reporting period was ¥16,000,000, with an unexpired balance of ¥2,550,000[67]. - The company’s total cash inflow from operating activities was 52,370,366.47 RMB in the first half of 2019, a slight increase from 51,386,831.54 RMB in the same period of 2018, indicating stable revenue generation[158]. Research and Development - The company increased R&D investment by 31.68% to ¥7,335,855.63, reflecting a commitment to innovation[51]. - The company has developed multiple chemical and traditional Chinese medicine products through its independent research and development efforts[26]. - The company provides clinical research services, including study design, implementation, monitoring, data management, and statistical analysis for pharmaceutical and medical device companies[25]. - The company has established five major R&D service platforms, significantly enhancing its preclinical research capabilities and technical team[38]. - The company is focusing on developing innovative drug clinical services and preclinical services to enhance its risk resistance capabilities[74]. Market and Industry Trends - The global CRO market size grew from USD 22 billion in 2010 to USD 35.8 billion in 2015, with a projected penetration rate increase from 18% in 2006 to 54% by 2020[27]. - The domestic CRO industry sales increased from RMB 18.8 billion in 2012 to RMB 46.5 billion in 2016, with a compound annual growth rate of 25.41%[28]. - The company anticipates continued high growth in the CRO industry, with projected sales reaching RMB 1,165 billion by 2021, reflecting a CAGR of 20.32% from 2017 to 2021[28]. - The NMPA's new policies in 2019 aim to streamline drug approval processes and encourage innovation, positively impacting the CRO industry[29]. Corporate Governance and Shareholder Matters - All directors attended the board meeting to review the report, ensuring comprehensive oversight[3]. - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[4]. - The company launched a stock option incentive plan for 48 employees to enhance talent retention and motivation[46]. - The company approved a stock option incentive plan, granting 2.695 million stock options at an exercise price of 11.60 CNY per share[89]. - The company adjusted its stock option plan, increasing the total number of options from 2.995 million to 3.8935 million, with a new exercise price of 8.91 CNY per share[90]. Risks and Challenges - The company faces risks related to contract execution, particularly in new drug development, which has long execution cycles and potential for delays or terminations due to various factors[75]. - The rapid growth of domestic CRO companies has intensified competition in the pharmaceutical R&D outsourcing industry, necessitating improved marketing and service levels[77]. - The company has established specific responsibility models in contracts to address potential delays and may incur penalty fees for project delays[76]. Financial Position - Total assets at the end of the reporting period were ¥610,039,290.91, a slight increase of 0.66% from ¥606,022,667.36 at the end of the previous year[17]. - The company's total liabilities amounted to CNY 184.05 million, a slight increase from CNY 182.31 million, showing a growth of 0.95%[139]. - The company's equity increased to CNY 425.99 million from CNY 423.71 million, a growth of 0.54%[139]. - The total owner's equity at the end of the period is 425,860,684.15 yuan, showing a decrease of 40,175,250.00 yuan compared to the previous period[170]. Compliance and Regulatory Matters - The financial report for the half-year period has not been audited[134]. - The company has not experienced any penalties or corrective actions during the reporting period[87]. - The company does not belong to the key pollutant discharge units as published by the environmental protection department[105].

Financial Performance - Total revenue for Q1 2019 was CNY 36,303,568.42, an increase of 14.75% compared to CNY 31,638,462.11 in the same period last year[7] - Net profit attributable to shareholders decreased by 72.78% to CNY 1,384,278.97 from CNY 5,085,215.54 year-on-year[7] - Basic earnings per share decreased by 75.00% to CNY 0.01 from CNY 0.04 in the same period last year[7] - The net profit attributable to shareholders was ¥1,384,278.97, a decrease of 72.78% compared to the same period last year, primarily due to a decline in overall gross margin[20] - Net profit for the current period was ¥698,928.65, a significant decrease of 85.3% from ¥4,747,210.14 in the previous period[55] - The company reported a decrease in operating profit to ¥584,292.99, down 86.4% from ¥4,293,528.49 in the previous period[55] - Total comprehensive income for the current period was ¥698,928.65, down from ¥4,747,210.14 in the previous period[56] Cash Flow - Net cash flow from operating activities fell by 76.56% to CNY 4,822,967.12, down from CNY 20,577,464.64 in the previous year[7] - Cash flow from operating activities decreased by 76.56% compared to the previous year, mainly due to increased employee salary payments and prior government subsidies received[21] - The net cash flow from operating activities for Q1 2019 was ¥4,822,967.12, a decrease from ¥20,577,464.64 in the previous year[63] - The total cash outflow from operating activities was ¥42,016,274.11, down from ¥61,961,709.22 in the previous year[63] - The net increase in cash and cash equivalents for Q1 2019 was ¥27,897,002.58, contrasting with a decrease of -¥19,868,796.58 in the previous year[64] Assets and Liabilities - Total assets at the end of the reporting period were CNY 612,590,864.13, a slight increase of 1.08% from CNY 606,022,667.36 at the end of the previous year[7] - Current liabilities rose to CNY 171,372,655.32 from CNY 165,155,933.51, marking an increase of about 4.0%[46] - Total liabilities amounted to CNY 188,222,945.84, up from CNY 182,309,914.41, reflecting an increase of about 3.0%[46] - Owner's equity totaled CNY 424,367,918.29, slightly up from CNY 423,712,752.95, indicating a marginal increase of about 0.2%[47] - Total assets increased to CNY 612,590,864.13 as of March 31, 2019, compared to CNY 606,022,667.36 at the end of 2018, reflecting a growth of approximately 1.0%[46] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,249[11] - The largest shareholder, Wang Tingchun, holds 38.61% of the shares, with 51,710,000 shares frozen[11] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[12] Operational Highlights - The company signed new contracts worth approximately ¥84 million during the reporting period, indicating ongoing business development efforts[22] - The proportion of total purchases from the top five suppliers decreased from 29.28% in the previous year to 19.79% in the current period, indicating reduced supplier concentration risk[26] - The top five customers accounted for 34.68% of total sales, down from 45.86% in the previous year, reflecting a diversification in the customer base[28] Investment and R&D - Investment income surged by 2819.17% to ¥672,510.19, attributed to returns from invested units and financial products[19] - Research and development expenses were ¥2,442,403.77, a decrease of 17.7% compared to ¥2,969,758.95 in the previous period[54] Risk Management and Strategy - The company has established a risk management strategy for contract execution, including provisions for service fee adjustments and loss sharing in case of unforeseen circumstances[31] - The company is actively monitoring policy changes in the pharmaceutical industry to mitigate risks associated with new drug approvals and regulatory requirements[30] - The company is facing increased market competition in the CRO industry, necessitating strategic planning and enhancement of core competencies[33] Stock Options and Incentives - The company has implemented a stock option incentive plan, granting 2,695,000 stock options to 48 incentive recipients[36] Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[40] - The company has not experienced any non-operational fund occupation by major shareholders during the reporting period[41] Financial Adjustments - The company has made adjustments under the new financial instrument standards, impacting the classification of certain financial assets[74] - The first quarter report was not audited, indicating preliminary financial data[75]

Financial Performance - The company's operating revenue for 2018 was RMB 172,042,840.49, representing a 31.58% increase compared to RMB 130,751,653.44 in 2017[18]. - The net profit attributable to shareholders for 2018 was RMB 7,399,910.67, a significant turnaround from a loss of RMB 24,488,599.54 in 2017, marking a 130.22% improvement[18]. - The net cash flow from operating activities was RMB 27,059,863.81, up 3.20% from RMB 26,219,594.71 in the previous year[18]. - The total assets at the end of 2018 amounted to RMB 606,022,667.36, reflecting a 5.45% increase from RMB 574,721,713.67 at the end of 2017[18]. - The company reported a basic earnings per share of RMB 0.060 for 2018, compared to a loss of RMB 0.180 per share in 2017, indicating a 133.33% improvement[18]. - The company achieved a weighted average return on equity of 1.80% in 2018, recovering from a negative 5.84% in 2017[18]. - The net profit after deducting non-recurring gains and losses was RMB 3,904,677.45, a 114.74% increase from a loss of RMB 26,482,881.36 in 2017[18]. - The company's total revenue for 2018 reached approximately ¥172.04 million, representing a year-on-year growth of 31.58%[51]. - Operating profit for the same period was approximately ¥14.88 million, showing a significant increase of 142.65% year-on-year[51]. - Net profit attributable to the parent company was approximately ¥7.40 million, reflecting a year-on-year growth of 130.22%[51]. Dividend and Share Capital - The company plans to distribute a cash dividend of 0.15 yuan per 10 shares and to increase capital by 3 shares per 10 shares from capital reserves, based on a total of 133,917,500 shares[6]. - The company plans to distribute a cash dividend of RMB 0.15 per 10 shares, totaling RMB 2,008,762.50 for the year 2018[121]. - The total distributable profit for the year is RMB 100,866,957.74, with the cash dividend accounting for 100% of the profit distribution[121]. - The cash dividend for 2018 represents 27.15% of the net profit attributable to the parent company[127]. - The company did not distribute any cash dividends in 2016 and 2017, focusing instead on reinvestment[125]. - The total number of shares outstanding as of December 31, 2018, is 133,917,500[123]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during its growth phase[121]. - The cash dividend distribution plan for 2018 is subject to approval at the annual shareholders' meeting[126]. Business Strategy and Development - The company emphasizes the importance of adapting to policy changes in the new drug development industry, which may impact R&D investments and drug registration processes[4]. - The company aims to enhance its risk resistance by leveraging its unique "one-stop service" advantage and focusing on innovative drug clinical services and preclinical services[4]. - The company has a strategic focus on expanding its business structure and development direction in response to regulatory changes[4]. - The company is committed to expanding its clinical research services to include medical devices and diagnostic formulations, achieving significant results in this area[106]. - The company aims to strengthen its collaboration with multinational pharmaceutical companies to participate in international multi-center clinical research services[106]. - The company plans to achieve 1-2 new drug clinical licenses annually through continuous development of its independent research and innovation capabilities[108]. - The company intends to actively invest in medical health product R&D services and other related sectors to enhance its project portfolio[110]. - The company is working towards obtaining GMP certification for its technology park production facility to provide contract development and manufacturing organization (CDMO) services[111]. Risk Management - The company acknowledges the competitive landscape in the CRO industry, which has intensified due to the rapid growth of domestic CRO companies, necessitating improved marketing and service levels[6]. - The company recognizes the risks associated with long-term contracts in new drug development, including potential delays and budget management challenges[5]. - The company has implemented a cautious approach to project execution, including strict process management to minimize project delays and associated penalties[5]. - The company is committed to maintaining good communication with clients to mitigate risks related to contract execution and potential disputes[5]. - The company recognizes risks related to policy changes that could impact new drug R&D investments and registration processes, and plans to adjust its business structure accordingly[112]. - The company faces competition risks from the rapid growth of domestic CRO companies, which necessitates improvements in marketing and service levels[116]. Research and Development - The company has developed five major R&D service platforms, including a traditional Chinese medicine active ingredient research platform, enhancing its clinical research capabilities[43]. - The company completed preclinical research for a traditional Chinese medicine compound for treating cholecystitis and submitted a clinical research application[76]. - The inhalation formulation platform has developed several liquid formulations for respiratory diseases, including asthma[78]. - In 2018, the company invested approximately ¥13.48 million in R&D, accounting for 7.84% of its operating revenue, compared to 7.97% in 2017[81]. - The number of R&D personnel increased to 122 in 2018, representing 19.81% of the total workforce, compared to 19.96% in 2017[81]. - The company has published more than 20 academic articles and applied for 16 patents[196]. Acquisitions and Partnerships - The company completed the acquisition of Humphries Pharmaceutical Consulting, enhancing its international drug registration capabilities and enabling simultaneous submissions to both NMPA and FDA[48]. - The company completed the acquisition of 51% of Hong Kong Yonghe Technology Co., enhancing its international medical registration service capabilities[58]. - The company has established a strategic cooperation agreement with the Zhaoqing government to form a CRO company and build a clinical research base, enhancing its drug development outsourcing capabilities[52]. - The company has established new wholly-owned subsidiaries, including Zhaoqing Boji Pharmaceutical Biotechnology Co., Ltd. and Zhaoqing Dingyuan Biomedical Co., Ltd., and acquired Hong Kong Yonghe Technology Co., Ltd. and its subsidiaries, which were included in the consolidated financial statements for the reporting period[139]. Compliance and Governance - The company has fulfilled all commitments made by its controlling shareholders and related parties during the reporting period[128]. - The company has strict compliance with share reduction commitments, ensuring that any proceeds from violations will revert to the company[130]. - The company has ensured compliance with all commitments made in the prospectus, maintaining investor trust[132]. - The company has committed to maintaining transparency and compliance with regulatory requirements in its operations[134]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[136]. - The company has adhered to its commitments regarding non-competition and fair transaction practices with related parties[134]. Market Outlook - The company's revenue from the CRO industry is projected to grow at a compound annual growth rate (CAGR) of 20.32% from 2017 to 2021, reaching 116.5 billion yuan by 2021[32]. - The global CRO market size was estimated at $43.09 billion in 2017, with a growth rate of 10%-12% expected[31]. - The CRO industry in China saw sales rise from 18.8 billion yuan in 2012 to 46.5 billion yuan in 2016, with a CAGR of 25.41%[32].

广州博济医药生物技术股份有限公司 2018 年第三季度报告全文 广州博济医药生物技术股份有限公司 2018 年第三季度报告 2018 年 10 月 1 广州博济医药生物技术股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王廷春、主管会计工作负责人欧秀清及会计机构负责人(会计主 管人员)欧秀清声明：保证季度报告中财务报表的真实、准确、完整。 2 广州博济医药生物技术股份有限公司 2018 年第三季度报告全文 单位：元 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 599,014,293.54 | | 574,721,713.67 | 4.23% | | 归属于上市公司股东的净 ...

Financial Performance - Total operating revenue for the reporting period reached ¥76,416,941.23, an increase of 40.13% compared to ¥54,534,659.60 in the same period last year[17]. - Net profit attributable to shareholders of the listed company was ¥5,739,929.49, a significant increase of 1,149.63% from ¥459,330.48 in the previous year[17]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,810,558.31, up 1,562.20% from a loss of ¥328,994.39 in the same period last year[17]. - Basic earnings per share increased to ¥0.0427, up 1,155.88% from ¥0.0034 in the same period last year[17]. - The company achieved total revenue of ¥76,416,941.23, representing a year-on-year growth of 40.13%, and a net profit attributable to the parent company of ¥5,739,929.49, up 1149.63% year-on-year[47]. - The company reported a net profit of -96,516.32 yuan for the first half of 2018, indicating a loss compared to the previous period[86]. - The net profit attributable to the parent company was ¥12,413,974.99, significantly up from ¥2,177,583.68 in the previous period, marking a growth of 469.5%[164]. - The total comprehensive income for the current period was ¥12,413,974.99, compared to ¥2,177,583.68 in the previous period, indicating a strong performance[165]. Cash Flow and Assets - Net cash flow from operating activities was ¥2,542,276.04, a turnaround from a negative cash flow of ¥3,632,466.22 in the previous year, representing a 169.99% improvement[17]. - Cash and cash equivalents at the end of the reporting period amounted to ¥78,358,255.47, representing 13.08% of total assets, a decrease of 9.36% compared to the previous year[62]. - The company's cash and cash equivalents decreased from RMB 133,244,445.65 at the beginning of the period to RMB 78,358,255.47 at the end of the period, representing a decline of approximately 41.2%[150]. - The ending balance of cash and cash equivalents decreased to 41,953,891.04 yuan from 72,489,339.43 yuan, a drop of 42%[173]. - Total assets at the end of the reporting period were ¥598,847,738.20, reflecting a 4.20% increase from ¥574,721,713.67 at the end of the previous year[17]. - The company reported a total asset of 34,378,284.1 yuan for Guangzhou Boji New Drug Clinical Research Co., Ltd., with a net profit of 2,220,524.60 yuan[85]. Investments and R&D - Long-term equity investments increased by 100.00% year-on-year, primarily due to investments in Harbin Shumande Pharmaceutical Technology Development Co., Ltd.[31]. - The company increased R&D investment to ¥5,571,144.94, a rise of 53.95% compared to the previous year, reflecting a commitment to innovation[55]. - Research and development expenses increased by 30% year-on-year, totaling 300 million RMB, focusing on innovative drug development[97]. - The company has established a talent development mechanism, conducting over 60 training sessions to enhance employee capabilities and quality control awareness[52]. Market and Industry Developments - The CRO industry is experiencing new opportunities due to the ongoing consistency evaluation of generic drugs and regulatory changes by CFDA[29]. - The approval process for clinical trials has been streamlined, significantly reducing the time required for new drugs to enter clinical trials[30]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2019[97]. - A strategic acquisition of a local biotech firm is anticipated to enhance the company's product pipeline and market reach[97]. Corporate Governance and Strategy - The company plans not to distribute cash dividends or bonus shares, nor to increase capital from reserves[4]. - All directors attended the board meeting to review the report, ensuring comprehensive oversight and governance[4]. - The company has established a risk management strategy to address potential contract execution delays and associated costs[87]. - The management emphasized a focus on sustainable growth and innovation as key strategies moving forward[97]. Shareholder Information - The largest shareholder, Wang Tingchun, holds 51,710,000 shares, accounting for 38.51% of total shares, with no changes during the reporting period[134]. - The total number of shareholders at the end of the reporting period was 11,043, with no preferred shareholders[134]. - The company has a total of 69,355,675 limited shares, with 67,639,125 shares released during the period[132]. Compliance and Reporting - The company does not have any discrepancies between financial reports prepared under international and Chinese accounting standards[19]. - The half-year financial report has not been audited[100]. - The financial report was approved by the board of directors on August 27, 2018[187]. - The company adheres to the "Enterprise Accounting Standards" and ensures that the financial statements reflect its financial status accurately[193].

Financial Performance - Total operating revenue for the first half of 2018 was CNY 76,416,941.23, representing a 40.13% increase compared to CNY 54,534,659.60 in the same period last year[17]. - Net profit attributable to shareholders of the listed company reached CNY 5,739,929.49, a significant increase of 1,149.63% from CNY 459,330.48 in the previous year[17]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 4,810,558.31, up 1,562.20% from a loss of CNY 328,994.39 in the same period last year[17]. - Basic earnings per share increased to CNY 0.0427, reflecting a growth of 1,155.88% compared to CNY 0.0034 in the previous year[17]. - The company achieved total revenue of ¥76,416,941.23, a year-on-year increase of 40.13%, with net profit attributable to the parent company reaching ¥5,739,929.49, up 1149.63%[47]. - The total comprehensive income for the current period is CNY 6,345,665.18, compared to CNY 121,109.24 in the previous period[156]. - The total comprehensive income for the first half of 2018 was CNY 2,177,583,000, reflecting an increase of 83.68% compared to the previous period[179]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 598,847,738.20, a 4.20% increase from CNY 574,721,713.67 at the end of the previous year[17]. - The company's total assets increased to ¥560,559,185.57 from ¥549,389,246.68, showing a growth of 2.1%[152]. - The total liabilities rose to ¥135,475,664.59, slightly down from ¥136,719,700.69, indicating a decrease of 0.9%[152]. - The equity attributable to shareholders increased to ¥425,083,520.98 from ¥412,669,545.99, reflecting a growth of 3.0%[152]. - Cash and cash equivalents at the end of the reporting period amounted to ¥78,358,255.47, representing 13.08% of total assets, a decrease of 9.36% compared to the previous year[61]. - The company's cash and cash equivalents decreased to RMB 78,358,255.47 from RMB 133,244,445.65, representing a decline of approximately 41.2%[145]. Cash Flow - The net cash flow from operating activities was negative CNY 4,233,000.43, a decline of 16.53% compared to negative CNY 3,632,466.22 in the same period last year[17]. - The net cash flow from operating activities was -12,515,208.63 yuan, compared to -546,594.48 yuan in the previous period, indicating a significant decline in operational performance[167]. - Total cash inflow from operating activities was 51,386,831.54 yuan, while cash outflow was 63,902,040.17 yuan, resulting in a net cash outflow of 12,515,208.63 yuan[167]. - The total cash outflow from investment activities was 51,595,842.40 yuan, significantly higher than the previous period's 25,301,857.47 yuan[167]. Investments and R&D - Long-term equity investments increased by 100.00% year-on-year, primarily due to investments in Harbin Shumande Pharmaceutical Technology Development Co., Ltd.[31]. - The company increased R&D investment to ¥5,571,144.94, a rise of 53.95% compared to the previous year, reflecting a commitment to innovation[55]. - The company engages in independent R&D for new drugs based on market trends and technical expertise[28]. - The company has provided clinical research services for nearly 600 projects, including 40 innovative drugs, since its establishment[35]. Corporate Governance and Compliance - All directors attended the board meeting to review the report, ensuring comprehensive oversight[3]. - The financial report was approved by the board of directors on August 27, 2018, ensuring compliance with the relevant accounting standards[181]. - The company has committed to not transferring or entrusting the management of its shares for a period of 16 months following the IPO, ensuring compliance with regulations[91]. - The company has adhered to all commitments regarding share transfers and management during the specified periods[92]. Market and Competitive Landscape - The competitive landscape in the domestic CRO market is intensifying, necessitating improvements in the company's marketing and service levels to maintain its market position[86]. - The company anticipates significant risks from policy changes in the new drug approval process, which could impact its business operations and revenue[83]. - The company plans to leverage its "one-stop service" advantage to adjust its business structure and enhance its capacity to withstand risks associated with policy fluctuations[83]. Subsidiaries and Acquisitions - The company has a total of 17 subsidiaries, including Guangzhou Boji New Drug Clinical Research Center Co., Ltd. and Beijing Zhongwei Bicheng International Pharmaceutical Technology Co., Ltd.[182]. - The acquisition of Humphries Pharmaceutical Consulting significantly enhanced the company's international drug registration capabilities, making it a leading CRO for simultaneous CFDA and FDA submissions[44]. - The company completed the acquisition of 51% of Hong Kong Yonghe Technology Co., enhancing its international registration service capabilities and expanding overseas business[51]. Shareholder Information - Major shareholder Wang Tingchun holds 51,710,000 shares, representing 38.51% of total shares[130]. - The total number of shareholders at the end of the reporting period was 11,043[129]. - The company has implemented a stock incentive plan affecting 931,000 shares for middle management and key employees[127].

Financial Performance - Total revenue for Q1 2018 reached ¥31,638,462.11, representing a 207.35% increase compared to ¥10,293,876.58 in the same period last year[7]. - Net profit attributable to shareholders was ¥5,085,215.54, a significant turnaround from a loss of ¥2,931,539.05 in the previous year, marking a 273.47% increase[7]. - The net cash flow from operating activities improved to ¥20,577,464.64, compared to a negative cash flow of ¥5,846,162.75 in the same period last year, reflecting a 451.98% increase[7]. - Basic earnings per share rose to ¥0.04, compared to a loss of ¥0.02 per share in the previous year, indicating a 300.00% improvement[7]. - The company's gross profit margin improved, leading to an operating profit of ¥4,293,528.49, a 197.85% increase from a loss of ¥4,387,668.89 in the previous year[23]. - The total profit for the period was CNY 4,502,598.48, with a year-on-year growth of 210.04%[24]. - The net profit for the current period was ¥4,747,210.14, a turnaround from a net loss of ¥3,195,151.13 in the previous period[55]. - The total comprehensive income for the current period was ¥4,747,210.14, compared to a comprehensive loss of ¥3,195,151.13 in the previous period[56]. Assets and Liabilities - Total assets at the end of the reporting period were ¥584,729,726.38, up 1.74% from ¥574,721,713.67 at the end of the previous year[7]. - Total current assets decreased from 321,346,677.45 to 285,374,713.38, a decline of approximately 11.2%[46]. - Total non-current assets increased from 253,375,036.22 to 299,355,013.00, an increase of approximately 18.1%[47]. - Total current liabilities increased from 152,067,982.13 to 157,225,423.28, an increase of approximately 4.8%[48]. - Total liabilities increased from 160,371,522.96 to 166,305,650.03, a rise of about 3.7%[48]. - Total equity attributable to shareholders increased from 404,231,119.59 to 408,141,882.80, an increase of approximately 1.0%[49]. Operational Strategy - The company plans to leverage its "one-stop service" advantage to adapt to policy changes in the new drug development sector, enhancing its risk resilience[9]. - The company aims to expand its innovative drug clinical services and preclinical services to strengthen its market position amid increasing competition in the CRO industry[12]. - The company has identified potential risks related to contract execution and market competition, and is implementing strategies to mitigate these risks[10][12]. - The company will adjust its business structure according to industry policies to ensure the feasibility of its fundraising investment projects[12]. Investment and Projects - The company completed the acquisition of Hong Kong Yonghe Technology Co., Ltd., enhancing its ability to provide dual registration services for CFDA and FDA[30]. - The clinical research service network expansion project has a total investment commitment of 91.25 million CNY, with 65.27 million CNY invested, achieving a progress rate of 71.53%[38]. - The pharmaceutical research center expansion project has a total investment commitment of 56.37 million CNY, with 49.89 million CNY invested, achieving a progress rate of 88.51%[38]. - The drug evaluation center construction project has a total investment commitment of 40.78 million CNY, with 24.65 million CNY invested, achieving a progress rate of 60.46%[38]. Cash Flow and Expenses - Cash flow from operating activities showed a strong performance with cash received from sales reaching ¥43,719,141.14, up from ¥21,402,969.91 in the previous period[62]. - The cash paid for purchasing goods and services was 16,709,428.99 CNY, up from 12,764,033.30 CNY in the previous period[63]. - The cash paid to employees was 12,401,143.42 CNY, compared to 11,401,618.89 CNY in the previous period, reflecting an increase in employee-related expenses[63]. - The company received 28,693,440.39 CNY from other operating activities, a significant rise from 2,679,985.93 CNY in the previous period[66]. Compliance and Governance - The company has not reported any violations regarding external guarantees during the reporting period[41]. - There are no non-operational fund occupations by controlling shareholders or related parties during the reporting period[42]. - The company has not identified any issues in the use and disclosure of raised funds[40].

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 25% in 2017, reaching a total of 500 million RMB[1]. - The company's operating revenue for 2017 was RMB 130,751,653.44, representing an increase of 81.22% compared to RMB 72,151,502.64 in 2016[19]. - The company achieved a revenue of approximately 130.75 million yuan in 2017, representing a year-on-year growth of 81.22%[48]. - The company reported a net profit attributable to shareholders of -24,488,599.54 CNY for the year 2017, with the parent company achieving a net profit of -18,667,181.06 CNY[115]. - The company reported a net loss of approximately 24.49 million yuan, a year-on-year decline of 1273.34%[48]. - The net cash flow from operating activities improved to RMB 26,219,594.71, a significant increase of 176.58% from a negative cash flow of RMB 34,237,314.74 in 2016[19]. - The company reported a gross margin of 27.39% for its service sector, with a significant increase in operating costs by 156.35% year-on-year[58]. Client and Market Expansion - User data indicates that the company has expanded its client base by 30%, now serving over 200 clients in the pharmaceutical sector[2]. - The company plans to expand its market presence by entering two new provinces in China by the end of 2018[5]. - The company is focused on expanding its CRO services for both domestic and international pharmaceutical companies[27]. - The company secured nearly 170 million yuan in new contracts for consistency evaluation in 2017, benefiting from policy incentives in the CRO industry[32]. - The company secured new contracts worth approximately 433 million yuan, a year-on-year increase of about 191%[48]. Research and Development - Investment in R&D has increased by 15%, focusing on innovative drug development and clinical trial services[4]. - The company has developed multiple chemical and traditional Chinese medicine varieties through independent research and development, distinguishing its CRO services from client-commissioned projects[31]. - The company is actively involved in the independent research and development of new drugs, aligning with market trends and leveraging its technical expertise for external technology transfer[31]. - The company is advancing a new drug for treating drug-resistant lung cancer, RUNNOR9591, which has received provincial funding and has potential for significant market impact[71]. - The company is collaborating with Guizhou BaiLing Pharmaceutical on the development of liraglutide, a promising diabetes treatment, indicating strong growth potential in this area[72]. - The company is focused on new drug research and development, with over 20 new drugs or reformulated products developed in preclinical research[198]. Operational Efficiency - The company provided a one-stop outsourcing service for drug development, including new drug research, clinical trials, and regulatory submissions[27]. - The company offers a comprehensive one-stop CRO service covering all stages of new drug development, enhancing efficiency and reducing costs for clients[37]. - The stability of the technical team is high, with 80% of mid-to-senior level staff having over six years of service, ensuring quality and expertise in service delivery[38]. - The company enhanced its clinical research capabilities with a nationwide service network of 37 monitoring service points[42]. - The company integrated advanced software and hardware systems, including Oracle OC/RDC and CTMS, to improve clinical data collection and management[40]. Strategic Initiatives - A strategic acquisition of a smaller CRO firm is expected to enhance the company's service offerings and market share[6]. - The company established a public service platform for biopharmaceutical research and development, with an investment of 52.56 million yuan and an area of 5000 square meters[49]. - The company established a new subsidiary, BoHuiKang (Beijing) Data Technology Co., Ltd., to provide clinical trial data management and statistical analysis services, aiming to diversify revenue streams[51]. - The company completed the construction of a pilot production platform in its biomedical technology park, covering an area of 20,266 square meters, and is in the process of obtaining GMP certification[52]. - The company acquired Humphries Pharmaceutical Consulting, enhancing its capability for dual registration in China and the U.S.[45]. Financial Management and Investments - The company has utilized ¥13,643.55 million of the raised funds from its initial public offering, with a remaining balance of ¥4,766.68 million in the dedicated account[87]. - The total committed investment for the clinical research service network expansion project is CNY 9,125.11 million, with a cumulative investment of CNY 6,356.58 million, achieving 69.66% of the planned investment by December 31, 2018[89]. - The company has committed to invest no less than 5% of the total fund amount in the health industry fund[145]. - The company reported a total of 23,736 million yuan in entrusted financial management, with an unexpired balance of 2,896 million yuan[155]. - The company has provided guarantees totaling 8,000 million yuan, with an actual guarantee amount of 779 million yuan, representing 1.93% of the company's net assets[151]. Risk Management - The company has identified potential risks related to policy changes in drug approval processes, which could impact future revenue streams[7]. - The company recognizes risks related to policy changes that could impact new drug R&D investments and registration processes, and plans to adjust its business structure accordingly[106]. - The company is aware of potential contract execution risks due to the complexity of new drug development and plans to establish clear communication with clients to mitigate these risks[107]. - The company is facing increased market competition in the pharmaceutical R&D outsourcing industry, necessitating improvements in marketing and service levels[109]. Shareholder and Governance - The company decided not to distribute cash dividends, issue bonus shares, or increase capital reserves for the fiscal year 2017[115]. - The company has committed to a lock-up period of 36 months for shares held prior to the IPO, with specific conditions for any share transfers thereafter[121]. - The company has established a plan to stabilize stock prices within three years post-IPO, including potential share buybacks[121]. - The company’s board of directors and senior management have committed to fulfilling their obligations under the stock price stabilization plan[125]. - The company has not engaged in any related party transactions during the reporting period[140]. Corporate Social Responsibility - The company emphasizes the protection of employee rights by providing competitive salaries and benefits, including social insurance and housing funds[158]. - The company has not been classified as a key pollutant discharge unit by environmental protection authorities[160]. - The company has not initiated any targeted poverty alleviation work nor has any plans for it in the reporting year[159].